NYVAC: a highly attenuated strain of vaccinia virus - PubMed (original) (raw)
NYVAC: a highly attenuated strain of vaccinia virus
J Tartaglia et al. Virology. 1992 May.
Abstract
A highly attenuated vaccinia virus strain, NYVAC (vP866), was derived from a plaque-cloned isolate of the Copenhagen vaccine strain by the precise deletion of 18 open reading frames (ORFs) from the viral genome. Among the ORFs deleted from NYVAC (vP866) are two genes involved in nucleotide metabolism, the thymidine kinase (ORF J2R) and the large subunit of the ribonucleotide reductase (ORF I4L); the gene encoding the viral hemagglutinin (ORF A56R); the remnant (ORF A26L) of a highly expressed gene responsible for the formation of A-type inclusion bodies; the disrupted gene (ORFs B13R/B14R) normally encoding a serine protease inhibitor; and a block of 12 ORFs bounded by two known viral host range regulatory functions (ORFs C7L through K1L). Within this block a secretory protein (ORF N1L) implicated in viral virulence and a functional complement 4b binding protein (ORF C3L) are encoded. The ORFs were deleted in a manner which prevents the synthesis of undesirable novel gene products. The attenuation characteristics of the derived NYVAC strain were compared in in vitro and in vivo studies with those of the Western Reserve (WR) laboratory strain, the New York City Board of Health vaccine strain (Wyeth), the parental plaque-cloned isolate (VC-2) of the Copenhagen vaccine strain used to derive NYVAC, and the avipox virus canarypox (ALVAC), which is naturally restricted for replication to avian species. The NYVAC strain was demonstrated to be highly attenuated by the following criteria: (a) no detectable induration or ulceration at the site of inoculation on rabbit skin; (b) rapid clearance of infectious virus from the intradermal site of inoculation on rabbit skin; (c) absence of testicular inflammation in nude mice; (d) greatly reduced virulence as demonstrated by the results of intracranial challenge of both 3-week-old or newborn mice; (e) greatly reduced pathogenicity and failure to disseminate in immunodeficient (nude or cyclophosphamide treated) mice; and (f) dramatically reduced ability to replicate on a variety of human tissue culture cells. Despite these highly attenuated characteristics, the NYVAC strain, as a vector, retains the ability to induce strong immune responses to extrinsic antigens.
Similar articles
- Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.
Parkinson JE, Smith GL. Parkinson JE, et al. Virology. 1994 Oct;204(1):376-90. doi: 10.1006/viro.1994.1542. Virology. 1994. PMID: 8091668 - Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.
Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M. Nájera JL, et al. PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406. PLoS One. 2010. PMID: 20613977 Free PMC article. - Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines.
Oguiura N, Spehner D, Drillien R. Oguiura N, et al. J Gen Virol. 1993 Jul;74 ( Pt 7):1409-13. doi: 10.1099/0022-1317-74-7-1409. J Gen Virol. 1993. PMID: 8336123 - Safe and effective poxvirus vectors--NYVAC and ALVAC.
Paoletti E, Tartaglia J, Taylor J. Paoletti E, et al. Dev Biol Stand. 1994;82:65-9. Dev Biol Stand. 1994. PMID: 7958484 Review. - The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.
Antoine G, Scheiflinger F, Dorner F, Falkner FG. Antoine G, et al. Virology. 1998 May 10;244(2):365-96. doi: 10.1006/viro.1998.9123. Virology. 1998. PMID: 9601507 Review.
Cited by
- Current Status of Poultry Recombinant Virus Vector Vaccine Development.
Wang H, Tian J, Zhao J, Zhao Y, Yang H, Zhang G. Wang H, et al. Vaccines (Basel). 2024 Jun 6;12(6):630. doi: 10.3390/vaccines12060630. Vaccines (Basel). 2024. PMID: 38932359 Free PMC article. Review. - Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.
Hsu J, Kim S, Anandasabapathy N. Hsu J, et al. Viruses. 2024 May 29;16(6):870. doi: 10.3390/v16060870. Viruses. 2024. PMID: 38932162 Free PMC article. Review. - Biology of Variola Virus.
Gopi P, Krishna G, Veettil MV. Gopi P, et al. Adv Exp Med Biol. 2024;1451:139-149. doi: 10.1007/978-3-031-57165-7_9. Adv Exp Med Biol. 2024. PMID: 38801576 Review. - Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S, Nishisaka Y, Fuji H, Marsh G, Maeda K, Ebihara H, Morikawa S, Shimojima M, Saijo M. Watanabe S, et al. PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38100536 Free PMC article. - Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.
Wang Y. Wang Y. Viruses. 2023 Aug 15;15(8):1742. doi: 10.3390/v15081742. Viruses. 2023. PMID: 37632084 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources